Delving into the Latest Updates on Ercalcitriol with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target

VDR

Mechanism

VDR agonists(Vitamin D receptor agonists)

Therapeutic Areas

Endocrinology and Metabolic DiseaseUrogenital Diseases

Active Indication-

Inactive Indication

Hyperparathyroidism, SecondaryKidney Failure, Chronic

Originator Organization

OPKO Health, Inc.

Active Organization-

Inactive Organization

OPKO IP Holdings II, Inc.

OPKO Health, Inc.

Drug Highest PhaseDiscontinuedPhase 1

First Approval Date-

Regulation-

Login to view timeline

Structure

Molecular FormulaC28H44O3

InChIKeyZGLHBRQAEXKACO-XJRQOBMKSA-N

CAS Registry60133-18-8

This study will compare CTAP201 with Doxercalciferol in patients with chronic kidney disease (CKD) and secondary hyperparathyroidism (SHPT), undergoing regular hemodialysis, at different dose strengths. This study will also investigate the levels of CTAP201 in the body over time and determine the safety of CTAP201.

Start Date01 Nov 2008

Sponsor / Collaborator

OPKO IP Holdings II, Inc.

100 Clinical Results associated with Ercalcitriol

Login to view more data

100 Translational Medicine associated with Ercalcitriol

Login to view more data

100 Patents (Medical) associated with Ercalcitriol

Login to view more data

1

Literatures (Medical) associated with Ercalcitriol

01 Oct 1990·Clinica Chimica ActaQ3 · MEDICINE

A sensitive radioimmunoassay using a monoclonal antibody that is equipotent for ercalcitriol and calcitriol (1,25-dihydroxy vitamin D2 and D3)

Q3 · MEDICINE

Article

Author: Berry, Jacqueline L. ; Cundall, J. Paul ; Still, Pamela E. ; White, Anne ; Mawer, E. Barbara

A monoclonal antibody has been used in a sensitive radioimmunoassay that measures 1,25-dihydroxyvitamin D2 (ercalcitriol) and 1,25-dihydroxyvitamin D3 (calcitriol) with equal potency. This important characteristic has not been reported for any other radioimmunoassay for 1,25-dihydroxyvitamin D. The two forms can be assayed in human serum together or individually after HPLC separation. Sample preparation entails acetonitrile extraction followed by C18-Sep-pak chromatography and HPLC. The assay measures 98% of added analyte, and achieves inter- and intra-assay coefficients of variation of 10.7% at 34 pg/ml and 7.8% at 81 pg/ml respectively. The limit of detection is 1.25 pg/tube and 50% displacement of bound ligand is achieved at 14 pg/tube. The reference interval is 20-50 pg/ml, mean 35. The correlation between results from the monoclonal radioimmunoassay and an established polyclonal antibody method was r = 0.98, slope 0.99. The assay has particular application in patients treated with vitamin D2 since 1,25-dihydroxyvitamin D2 can now be measured accurately in the presence of 1,25-dihydroxyvitamin D3.

100 Deals associated with Ercalcitriol

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Kidney Failure, Chronic	Phase 1	US	OPKO IP Holdings II, Inc.	01 Nov 2008
Hyperparathyroidism, Secondary	Phase 1	-	OPKO Health, Inc.	-
Hyperparathyroidism, Secondary	Phase 1	-	OPKO Health, Inc.	-